DENDREON CORP
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | |
|---|---|---|---|---|---|---|
| Revenue | $67.6M | $82.1M | $341.6M | $48.1M | $101,000 | $111,000 |
| Operating income | −$243.0M | −$339.8M | −$291.7M | −$292.2M | −$100.0M | −$70.5M |
| Net income | −$72.0M | −$103.9M | −$337.8M | −$439.5M | −$220.2M | −$71.6M |
| Total assets | $434.4M | $721.1M | $1.00B | $604.0M | $735.4M | — |
| Total liabilities | — | — | — | — | — | — |
| Equity | −$247.7M | $34.6M | $352.6M | $492.8M | $503.6M | $27.0M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 156.1M | 153.8M | 145.5M | 147.4M | 131.1M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2013- Operating margin
- −359.5%
- Net margin
- −106.5%
- Return on equity
- 29.1%
- Return on assets
- −16.6%
- Return on capital (ROCE)
- −73.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-1.59
- Revenue growth (YoY)
- −17.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2013- Accruals / assets
- 33.5%high accruals
- Piotroski F-Score
- 2/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 5 warning● 1 good- Negative shareholder equity
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
- Strong return on equity (>15%)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Pacheco SilvioOfficer — SVP, Sales and Marketing | Feb 23, 2015 | Tax withholding | 5,777 | $0.05 |
| Brophy KarenOfficer — VP, Human Resources | Feb 23, 2015 | Tax withholding | 758 | $0.05 |
| Brophy KarenOfficer — VP, Human Resources | Feb 19, 2015 | Sell | 2,309 | $0.07 |
| Crotty RobertOfficer — EVP, General Counsel | Feb 17, 2015 | Sell | 21,764 | $0.08 |
| Pacheco SilvioOfficer — SVP, Sales and Marketing | Feb 17, 2015 | Sell | 2,500 | $0.08 |
| Monteith WilliamOfficer — EVP, Technical Operations | Feb 13, 2015 | Sell | 1,284 | $0.09 |
| Cox GregOfficer — EVP, CFO & Treasurer | Feb 13, 2015 | Sell | 110,133 | $0.09 |
| Sandler Andrew SethOfficer — EVP, Chief Medical Officer | Feb 13, 2015 | Sell | 7,791 | $0.09 |
| Crotty RobertOfficer — EVP, General Counsel | Jan 31, 2015 | Tax withholding | 470 | $0.16 |
| Monteith WilliamOfficer — EVP, Technical Operations | Jan 20, 2015 | Tax withholding | 240 | $0.17 |
| Cox GregOfficer — VP, Interim CFO & Treasurer | Jan 20, 2015 | Tax withholding | 193 | $0.17 |
| Sandler Andrew SethOfficer — EVP, Chief Medical Officer | Jan 13, 2015 | Tax withholding | 6,121 | $0.09 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Director / officer change · Regulation FD disclosureJun 10, 2015
- Bankruptcy or receivership · Modified shareholder rights · Regulation FD disclosureJun 3, 2015
- Regulation FD disclosureJun 2, 2015
- Regulation FD disclosure · Other material eventMay 21, 2015
- Regulation FD disclosureApr 21, 2015
- Regulation FD disclosureApr 17, 2015
- Other material eventApr 8, 2015
- Regulation FD disclosureMar 25, 2015
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KFORM 8-KJun 10, 2015
- 8-KJun 3, 2015
- 8-KJun 2, 2015
- 8-KFORM 8-KMay 21, 2015
- 8-KApr 21, 2015
- 8-KApr 17, 2015
- 8-KFORM 8-KApr 8, 2015
- 8-KFORM 8-KMar 25, 2015
- 8-KMar 11, 2015
- 8-KMar 6, 2015
- 8-KFORM 8-KFeb 27, 2015
- 4FORM 4 SUBMISSIONFeb 25, 2015
- 4FORM 4 SUBMISSIONFeb 25, 2015
- 8-KFeb 23, 2015
- 8-KFORM 8-KFeb 20, 2015
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.